B.Sc. (Dunelm), M.Sc., Ph.D., C.Stat., RSS Fellow
Telephone: 01223 (7) 61762
Mark is a Senior Research Associate in the Cambridge Research Methods Hub (CRMH) & the Behaviour and Health Research Unit (BHRU). He has a background within both academia (medical consultancy at Sheffield University & health-care research at Manchester University) and also the Pharmaceutical industry (statistical genetics, safety assessment & drug discovery for AstraZeneca, and clinical studies for GSK/Novartis).
He has reviewed ~60 papers, a number of NIHR grants and is a panel member for a national grant awarding body and sat for two years on the RSS Medical Statistics committee. The majority of his ~50 publications relate to a variety of different types of healthcare studies.
– B.Sc. Mathematics, Durham, 1991
– M.Sc. Statistics, Sheffield, 1995
– Ph.D. Statistics & Ecology, Sheffield, 2001
Over the past few years, his work has involved supporting multiple projects at the BHRU covering such statistical techniques as meta-analysis, Bayesian meta-regression, generalized linear models, zero-inflated repeated-measures regression, hurdle models, GEE, GAMLSS, machine learning approaches, hierarchical models. Previous projects have included Rasch analysis, assessing agreement, questionnaire development, survey data analysis, biomarker discovery, statistical genetics, statistical process control, adaptive trial design, SW-CRCT design…
These tools support his interest in the field of Healthcare Statistics, and more specifically Trial Design; especially sample size estimation.
Guest lecturer on 2018 M.Sc. Biostatistics course
Lecturer on M.Res. i) Statistics, ii) Design courses, Manchester University 2011-2016
Impact of increasing the proportion of healthier foods available on energy purchased in worksite cafeterias: A stepped wedge randomized controlled pilot trial. R Pechey, E Cartwright, M Pilling, GJ Hollands, M Vasiljevic, SA Jebb, TM Marteau. 2019. Appetite 133, 286-296.
The oral selective oestrogen receptor degrader (SERD) AZD9496 is comparable to fulvestrant in antagonising ER and circumventing endocrine resistance. A Nardone, H Weir, O Delpuech, H Brown, C De Angelis, ML Cataldo, X Fu, MJ Shea, T Mitchell, J Veeraraghavan, C Nagi, M Pilling, MF Rimawi, M Trivedi, SG Hilsenbeck, GC Chamness, R Jeselsohn, CK Osborne, R Schiff. 2019. British Journal of Cancer 120 (3), 331.
Impact of calorie labelling in worksite cafeterias: A stepped wedge randomised controlled pilot trial. M Vasiljevic, E Cartwright, M Pilling, MM Lee, G Bignardi, R Pechey, G Hollands, S Jebb, & T Marteau. 2018. International Journal of Behavioural Nutrition and Physical Activity
A multi-center preclinical study of Gadoxetate DCE-MRI in rats as a biomarker of drug induced inhibition of liver transporter function. A Karageorgis, S Lenhard, B Yerby, M Forsgren, S Liachenko, E Johansson, M Pilling, R Peterson, X Yang, D Williams, S Ungersma, R Morgan, K Brouwer, B Jucker, P Hockings. 2018. Plos One.
Utility of spherical human liver microtissues for prediction of clinical drug-induced liver injury. W Proctor, A Foster, J Vogt, C Summers, B Middleton, M Pilling, D Shienson, M Kijanska, S Ströbel, J Kelm, P Morgan, S Messner, D Williams. 2017. Arch Toxicol. 91(8), 2849-2863.
Feasibility study to prevent falls in older people who are sight impaired: the VIP2UK randomised controlled trial. H Waterman, C Ballinger, C Brundle, S Chastin, H Gage, R Harper, D Henson, B Laventure, L McEvoy, M Pilling, N Olleveant, D A Skelton, P Stanford, C Todd. 2016. Trials 17(1), 464.
The theoretical and practical determination of clinical cut-offs for the British Sign Language versions of PHQ-9 and GAD-7. R Belk, M Pilling, KD Rogers, K Lovell, A Young. 2016. BMC Psychiatry 16:372.
Recommendations for managing missing data, attrition and response shift in palliative and end-of-life care research : Part of the MORECare research method guidance on statistical issues. N Preston, P Fayers, S Walters, M Pilling, G Grande, V Short, E Owen-Jones, C Evans, H Benalia, I Higginson, C Todd. 2013. Palliative Medicine 27(10) 899-907.
An Exploratory Study to Clarify the Cluster of Symptoms Predictive of Chemotherapy-Related Nausea Using Random Forest Modeling. A Molassiotis, C Farrell, K Bourne, SG Brearley, M Pilling. 2012. Journal of Pain and Symptom Management 44(5), 692-703.
He also sits on the grant assessment panel of the NC3Rs (National Centre for the Replacement, Refinement and Reduction of Animals in Research), is currently a book reviewer for the RSS and an MCR member of Trinity Hall Cambridge.
Additionally, Mark acts as an independent Statistician on trial steering and data monitoring & ethics committee (TSDMEC) for the “Caring for Me and You: A toolkit for carers of people with dementia” trial in Oxford, and also on the independent data monitoring committee for the “PreventIT” trial in Manchester.
Within my role I regularly give presentations on statistical topics, and assists with Ph.D. student’s projects within the BHRU group.